Nohla Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
NLA101 in Adults Receiving High Dose Chemotherapy for AML
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT03301597
- Locations
- 🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01701323
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 163
- Registration Number
- NCT01690520
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in Remission
- Interventions
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01175785
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01031368
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States